Complement C3 mediated targeting of liposomes to granulocytic myeloid derived suppressor cells

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 6, 2015, Pages 1355-1363

  Kullberg, Max ^a   Martinson, Holly ^a   Mann, Kristine ^a   Anchordoquy, Thomas J ^b  

^a UNIVERSITY OF ALASKA ANCHORAGE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Cancer; Complement C3; Immunotherapy; Liposome; MDSC; Myeloid derived suppressor cells

Indexed keywords

COVALENT BONDS; CYTOLOGY; DISEASES; IMMUNE SYSTEM; LIPOSOMES; MAMMALS; TUMORS;

CANCER; COMPLEMENT C3; IMMUNOTHERAPY; INTRAVENOUS INJECTIONS; LIPOSOMAL DRUG DELIVERY SYSTEMS; MDSC; SYSTEMIC ADMINISTRATION; TARGETED DRUG DELIVERY;

CELLS;

CD11B ANTIGEN; CELL MARKER; COMPLEMENT COMPONENT C3; IMMUNOGLOBULIN G; IMMUNOLOGIC AGENT; LIPOSOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL AGGREGATION; CELL ISOLATION; CELL POPULATION; CONTROLLED STUDY; DISULFIDE BOND; ENZYME ACTIVATION; FLOW CYTOMETRY; GRANULOCYTIC MYELOID DERIVED SUPPRESSOR CELL; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIPOSOMAL DELIVERY; MACROPHAGE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TARGET CELL; ANIMAL; BAGG ALBINO MOUSE; GRANULOCYTE; IMMUNOTHERAPY; KNOCKOUT MOUSE; METABOLISM; NEOPLASMS, EXPERIMENTAL;

ANIMALS; COMPLEMENT C3; GRANULOCYTES; IMMUNOTHERAPY; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL;

EID: 84937127869     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.03.010     Document Type: Article

References (28)

1. Khaled Y.S., Ammori B.J., Elkord E. Myeloid-derived suppressor cells in cancer: Recent progress and prospects. Immunol Cell Biol 2013, 91:493-502.
2. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009, 58:49-59.
3. Mirza N., Fishman M., Fricke I., Dunn M., Neuger A.M., Frost T.J., et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006, 66:9299-9307.
4. Ugel S., Delpozzo F., Desantis G., Papalini F., Simonato F., Sonda N., et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr Opin Pharmacol 2009, 9:470-481.
5. Najjar Y.G., Finke J.H. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front Oncol 2013, 3:49.
6. Raber P.L., Thevenot P., Sierra R., Wyczechowska D., Halle D., Ramirez M.E., et al. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int J Cancer 2014, 134:2853-2864.
7. Ribechini E., Greifenberg V., Sandwick S., Lutz M.B. Subsets, expansion and activation of myeloid-derived suppressor cells. Med Microbiol Immunol 2010, 199:273-281.
8. Favaloro J., Liyadipitiya T., Brown R., Yang S., Suen H., Woodland N., et al. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leuk Lymphoma 2014, 55:2893-2900.
9. Moghimi S.M., Szebeni J. Stealth liposomes and long circulating nanoparticles: Critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003, 42:463-478.
10. Medina O.P., Zhu Y., Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des 2004, 10:2981-2989.
11. Ohara Y., Oda T., Yamada K., Hashimoto S., Akashi Y., Miyamoto R., et al. Effective delivery of chemotherapeutic nanoparticles by depleting host Kupffer cells. Int J Cancer 2012, 131:2402-2410.
12. Gosk S., Moos T., Gottstein C., Bendas G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 2008, 1778:854-863.
13. Cheng W.W., Allen T.M. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: A comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release 2008, 126:50-58.
14. van der Meel R., Vehmeijer L.J., Kok R.J., Storm G., van Gaal E.V. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Adv Drug Deliv Rev 2013, 65:1284-1298.
15. Kullberg M., Mann K., Anchordoquy T.J. Targeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO. Mol Pharm 2012, 9:2000-2008.
16. Sun X., Zhang G., Patel D., Stephens D., Gobin A.M. Targeted cancer therapy by immunoconjugated gold-gold sulfide nanoparticles using protein G as a cofactor. Ann Biomed Eng 2012, 40:2131-2139.
17. Mitchell D.A., Ilyas R., Dodds A.W., Sim R.B. Enzyme-independent, orientation-selective conjugation of whole human complement C3 to protein surfaces. J Immunol Methods 2008, 337:49-54.
18. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
19. Cao Y., Slaney C.Y., Bidwell B.N., Parker B.S., Johnstone C.N., Rautela J., et al. Bmp4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity. Cancer Res 2014, 74:5091-5102.
20. Keskinov A.A., Shurin M.R. Myeloid regulatory cells in tumor spreading and metastasis. Immunobiology 2014, 220:236-242.
21. Duncan R., Sat-Klopsch Y.N., Burger A.M., Bibby M.C., Fiebig H.H., Sausville E.A. Validation of tumour models for use in anticancer nanomedicine evaluation: The EPR effect and cathepsin B-mediated drug release rate. Cancer Chemother Pharmacol 2013, 72:417-427.
22. Lammers T., Kiessling F., Hennink W.E., Storm G. Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress. J Control Release 2012, 161:175-187.
23. Alcorlo M., Martinez-Barricarte R., Fernandez F.J., Rodriguez-Gallego C., Round A., Vega M.C., et al. Unique structure of iC3b resolved at a resolution of 24 Å by 3D-electron microscopy. Proc Natl Acad Sci U S A 2011, 108:13236-13240.
24. Ueha S., Shand F.H., Matsushima K. Myeloid cell population dynamics in healthy and tumor-bearing mice. Int Immunopharmacol 2011, 11:783-788.
25. Gabrilovich D.I., Velders M.P., Sotomayor E.M., Kast W.M. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J Immunol 2001, 166:5398-5406.
26. Kusmartsev S., Cheng F.D., Yu B., Nefedova Y., Sotomayor E., Lush R., et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 2003, 63:4441-4449.
27. Mehta K., Sadeghi T., McQueen T., Lopez-Berestein G. Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid. Leuk Res 1994, 18:587-596.
28. Ozpolat B., Lopez-Berestein G., Adamson P., Fu C.J., Williams A.H. Pharmacokinetics of intravenously administered liposomal all-trans-retinoic acid (ATRA) and orally administered ATRA in healthy volunteers. J Pharm Pharm Sci 2003, 6:292-301.